Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis 2019
2019 Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging with a Point-of-Care Perfusion Phantom: A Pilot Study 2019
2019 HTX-019: Polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis 2019
2019 Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE) 2019
2018 Should palonosetron be a preferred 5-HT 3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis 2018
2018 Phase III safety study of intravenous NEPA: A novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy 2018
2018 Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy 2018
2018 Safety of Polysorbate 80 in the Oncology Setting 2018
2018 Managing Nausea and Vomiting in Patients With Cancer: What Works 2018
2018 Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting 2018
2017 Thalidomide: Rebirth of a gestational antiemetic? 2017
2017 Recent developments in the clinical pharmacology of rolapitant: Subanalyses in specific populations 2017
2017 Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients 2017
2017 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy 2017
2017 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting 2017
2017 Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy 2017
2016 The authors reply 2016
2016 Rolapitant hydrochloride: Prophylactic treatment for chemotherapy-induced nausea and vomiting 2016
2016 Olanzapine for the prevention of chemotherapy-induced nausea and vomiting 2016
2016 Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis 2016
2016 Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting 2016
2016 Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy 2016
2016 Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting 2016
2016 The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting 2016
2016 Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review 2016
2015 5-HT3receptors as important mediators of nausea and vomiting due to chemotherapy 2015
2015 Rolapitant for the treatment of chemotherapy-induced nausea and vomiting 2015
2015 Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: Two randomised, active-controlled, double-blind, phase 3 trials 2015
2015 Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: A randomised, active-controlled, double-blind, phase 3 trial 2015
2015 Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting 2015
2014 Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV) 2014
2014 Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting 2014
2014 Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. 2014
2014 Clinical trial data in chemotherapy-induced nausea and vomiting 2014
2014 Clinical trial data in chemotherapy-induced nausea and vomiting. 2014
2014 Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting 2014
2014 Palonosetron for the treatment of chemotherapy-induced nausea and vomiting 2014
2013 Selective photocrosslinking of functional ligands to antibodies viatheconserved nucleotide binding site 2013
2013 The current status of the use of palonosetron 2013
2013 The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy 2013
2013 Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents 2013
2012 A Review of the prevention of nausea and vomiting induced by chemotherapy 2012
2012 Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo 2012
2012 Treatment of chemotherapy-induced nausea 2012
2011 Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography 2011
2011 Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial 2011
2011 An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia 2011
2010 Treatment of cancer-related anorexia with olanzapine and megestrol acetate: A randomized trial 2010
2010 Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer 2010
2009 Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy. 2009
2009 Palonosetron: A second generation 5-hydroxytryptamine 3 receptor antagonist Palonosetron Navari 2009
2009 Treatment of chemotherapy-induced breakthrough nauea and vomiting. 2009
2009 Pharmacological management of chemotherapy-induced nausea and vomiting 2009
2009 Antiemetic control: Toward a new standard of care for emetogenic chemotherapy 2009
2008 Fosaprepitant: A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting 2008
2008 Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy 2008
2008 Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activities 2008
2008 Treatment of cancer-related anorexia with olanzapine and megestrol acetate. 2008
2007 Fosaprepitant (MK-0517): A neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting 2007
2007 A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study 2007
2007 Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting 2007
2007 Prevention of emesis from multiple-day and high-dose chemotherapy regimens 2007
2006 Palonosetron: A second-generation 5-hydroxytryptamine receptor antagonist 2006
2006 A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV). 2006
2006 Emerging drugs for chemotherapy-induced emesis 2006
2006 New approaches to chemotherapy-induced nausea and vomiting: From neuropharmacology to clinical investigations 2006
2006 Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting 2006
2005 Cathepsin E is a specific marker of dysplasia in APC Min/+ mouse intestine 2005
2005 Symptomatic treatment of infections in patients with advanced cancer receiving hospice care 2005
2005 A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study 2005
2005 Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. 2005
2004 Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: Summary of clinical trials 2004
2004 A phase I trial of olanzapine (zyprexa) for the prevention of delayed emesis in cancer patients: A hoosier oncology group study 2004
2004 A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV). 2004
2004 The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC (Min/+) mice 2004
2004 Aprepitant: A neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting 2004
2004 Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists. 2004
2003 Comment: Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists [6] (multiple letters) 2003
2003 Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists 2003
2003 Antimicrobial use in patients with advanced cancer receiving hospice care 2003
2003 Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. 2003
2002 Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: A randomized controlled trial 2002
2002 Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma 2002
2001 International study in premedical education 2001
2000 Preferences of patients with advanced cancer for hospice care [2] 2000
1999 Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist [4] (multiple letters) 1999
1999 Reduction of cisplatin-induced emesis by a selective neurokinin-1- receptor antagonist 1999
1999 A prisoner with chronic myeloid leukemia 1999
1999 Use of placebos in delayed-emesis studies [6] (multiple letters) 1999
1998 Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy 1998
1997 The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy 1997
1997 Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis 1997
1997 Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy 1997
1997 Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy 1997
1997 Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone 1997
1996 Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma 1996
1996 Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer 1996
1996 Is oral ondansetron really efficacious in the control of cisplatin- induced delayed emesis? [1] 1996
1995 Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis 1995
1995 Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo 1995
1994 Treatment of cancer-associated hypercalcemia: Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone 1994
1994 Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin 1994
1993 Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy 1993
1993 Protein turnover in advanced lung cancer patients 1993
1992 Glucose metabolism in advanced lung cancer patients. 1992
1992 Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting 1992
1991 Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor 1991
1989 Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy 1989
1987 Treatment of marrow graft recipients with thymopentin 1987
1986 Laminar air flow isolation and decontamination: A prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patients 1986
1984 Hypothermia. 1984
1984 Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants 1984
1983 Pneumatosis cystoides intestinalis following allogeneic marrow transplantation 1983
1983 The peripheral blood smear in heat stroke. An aid to diagnosis. 1983
1983 Bone marrow necrosis in acute leukemia 1983
1983 Mycobacterial infections in marrow transplant patients 1983
1982 Routine Endoscopy in Upper-Gastrointestinal Tract Bleeding 1982
1981 Renal Adenocarcinoma Associated With Multiple Simple Cysts 1981
1980 Functional, morphological, and metabolic abnormalities of the cerebral microcirculation after concussive brain injury in cats 1980
1979 Oxygen consumption of pial arteries 1979
1979 Oxygen consumption of pial arteries 1979
1978 Inhibition of rat bronchiolar oxygen consumption by plasma proteins 1978
1978 Role of tissue hypoxia in local regulation of cerebral microcirculation. 1978
1978 Responses of cerebral arteries and arterioles to acute hypotension and hypertension. 1978
1978 Comparison of the open skull and cranial window preparations in the study of the cerebral microcirculation 1978
1978 Responses of cerebral arteries and arterioles to acute hypotension and hypertension 1978
1977 Mass transfer properties of gases in fluorocarbons 1977
1977 Effects of induced acute hypertension on the oxygen consumption and responsiveness of cerebral arterioles 1977
1977 In Vitro Depression of Tissue Oxygen Uptake by Liquid Fluorocarbon Prepared as Artificial Blood 1977
1977 Oxygen consumption of pial arteries 1977
1976 Fluorocarbon effects on tissue OO2in vitro 1976
1975 Effects of vitamins A and E on rat tissue lipids 1975
1974 Laboratory experiments using nicotine 1974
1974 Effect of plasma proteins on oxygen diffusion in the pulmonary capillaries 1974
1971 Transport in human plasma. 1971
1971 A predictive theory for diffusion in polymer and protein solutions 1971
1969 Blood flow modeling with microcapsular suspensions 1969
1968 Prediction of the sigma effect in blood flow. 1968

Book

Year Title Altmetric
2016 Management of chemotherapy-induced nausea and vomiting: New agents and new uses of current agents 2016

Chapter

Year Title Altmetric
2018 Antiemetics.  587-601. 2018
2016 Clinical management of CINV.  157-162. 2016
2016 Conclusions.  177-178. 2016
2016 Future directions.  179-181. 2016
2016 Introduction.  1-3. 2016
2016 Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.  107-120. 2016
2016 Treatment of chemotherapy-induced nausea.  163-176. 2016

Research Overview

  • Supportive Care in Oncology, Antiemetics
  • Investigator On

  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2019 - 2025
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Education And Training

  • UAB, Internship 1978
  • University of Alabama at Birmingham, Residency 1980
  • University of Alabama at Birmingham, Residency 1978
  • University of Washington School of Medicine and Medical Centers, Postdoctoral Fellowship 1983
  • Full Name

  • Rudolph Navari